Key facts
- This page summarizes Amos Bar-Shalev's Form 4 filing for Protalix BioTherapeutics, Inc. (PLX).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 19 Nov 2025, 16:34.
Amos Bar-Shalev - 18 Nov 2025 Form 4 Insider Report for Protalix BioTherapeutics, Inc. (PLX)
- Reporting relationship
- Director
- Issuer ticker
- PLX
- Reported as of
- 18 Nov 2025
- Net transaction value
- -$314
- SEC form
- 4
- Accepted by SEC
- 19 Nov 2025, 16:34:55 UTC
- Prior SEC filing
- 04 Sep 2025
- Next SEC filing
- 04 Sep 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Joseph R. Magnas, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Amos Bar-Shalev filed Form 4 for Protalix BioTherapeutics, Inc. (PLX) on 19 Nov 2025.
Change
- Previous filing in this sequence was filed on 04 Sep 2025.
- Current net transaction value: -$314.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001385113
Primary reporting owner
Bar-Shalev Amos
- Relationship
- Director
- Address
- C/O PROTALIX BIOTHERAPEUTICS, INC., 2 SNUNIT STREET SCIENCE PARK, POB 455, CARMIEL, ISRAEL
- Signature
- /s/ Joseph R. Magnas, Attorney-in-Fact
- Signature date
- 19 Nov 2025
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
PLX
transaction
Common Stock
Sale
- Transaction value
- $314
- Shares
- -168
- Change %
- -100%
- Price
- $1.87
- Shares after
- 0
- Date
- 18 Nov 2025
- Ownership
- Direct
PLX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 7,500
- Date
- 18 Nov 2025
- Ownership
- By Trust
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued under the Amended and Restated Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended must be registered in the name of a trustee.